NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrends Get Aravive alerts: Email Address About Aravive Stock (NASDAQ:ARAV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aravive alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Read More… FDA’s hidden signal greenlights biotech winners — 97% of the time (Ad)The FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow. Click here to find out how you can get in before the FDA’s potential signal. Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Stock News HeadlinesPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightApril 2, 2024 | finance.yahoo.comFDA’s hidden signal greenlights biotech winners — 97% of the timeThe FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow.September 29, 2024 | Weiss Ratings (Ad)Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comCrude Oil Rises Over 1%; Processa Pharmaceuticals Shares SlideJanuary 18, 2024 | msn.comWhy Is Nuvve (NVVE) Stock Down 31% Today?January 18, 2024 | msn.comWhy Is Aravive (ARAV) Stock Down 52% Today?January 18, 2024 | markets.businessinsider.comAravive Shares Drop 53%, Company to Delist and Deregister StockJanuary 17, 2024 | marketwatch.comSee More Headlines ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? Aravive's stock was trading at $0.1237 at the beginning of 2024. Since then, ARAV shares have decreased by 67.6% and is now trading at $0.0401. View the best growth stocks for 2024 here. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) released its quarterly earnings results on Wednesday, October, 27th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.07. The business had revenue of $2.41 million for the quarter, compared to the consensus estimate of $2.36 million. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings10/27/2021Today9/29/2024Next Earnings (Estimated)9/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$6.99 million Price / Sales0.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.22Miscellaneous Outstanding Shares73,563,000Free Float29,131,000Market Cap$2.95 million OptionableNo Data Beta2.19 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ARAV) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredUrgent 2024 Election Summit [link enclosed]With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.